IOMAB-CAR-T Followed by CAR-T Cell Therapy in R/R DLBCL

This trial is testing a new approach to preparing patients for CAR-T cell therapy in relapsed or treatment-resistant diffuse large B-cell lymphoma (DLBCL). Instead of standard lymphodepletion chemotherapy before CAR-T infusion, this study uses IOMAB-ACT — a targeted radioimmunotherapy drug — to clear space in the bone marrow for the CAR-T cells to grow. **You may be eligible if...** - You have been diagnosed with relapsed or refractory DLBCL (de novo, transformed from follicular lymphoma, or high-grade B-cell lymphoma) - You have received at least one prior chemoimmunotherapy regimen that included an anthracycline and a CD20-directed therapy (like rituximab) - You are considered eligible for standard-of-care CAR-T cell therapy by your treatment team - You meet standard CAR-T eligibility requirements regarding organ function and performance status **You may NOT be eligible if...** - Your lymphoma has not relapsed or is still responding to current treatment - You have not yet tried standard eligible therapies - Your organ function does not support CAR-T therapy - You have active uncontrolled infections or other serious conditions Talk to your doctor to see if this trial is right for you.